The government is in the final stages of due diligence to ink a supply deal with Serum Institute of India and Bharat Biotech, which have got approval for emergency use of their vaccines
Dry ice, which is used to pack the vaccine, transforms into carbon dioxide gas at temperatures higher than -78 degrees Celsius and is therefore classified as "dangerous goods" by ICAO
Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts
Government has asked airlines to get ready to transport 30 tonnes of vaccines immediately
A million jabs to be delivered in January and the remainder the following month
The final contract is expected to be signed soon
While Covishield could erode a third of states' health bill if they bear the full cost, approval of the Pfizer jab would double the health spend
The health ministry is prepared to roll out the Covid vaccine within 10 days of the emergency use authorisation, which was granted to two companies on January 3
The Indian government may be looking to put pressure on Serum to lower its prices, as seen by its controversial decision to greenlight a rival vaccine
Health personnel succh as doctors and nurses and frontline workers such as police personnel, home guards won't have to register themselves online to get the vaccine
Adar Poonawalla and Krishna Ella issue joint statement saying they would work together to roll out Covid-19 vaccine
A FinMin report says India is witnessing a 'V-shaped' economic recovery since June; China court awards death sentence to former business executive.
The more important task right now is of saving the lives and livelihoods of populations in India and around the world, a joint statement by both companies said
The media and opposition figures have justifiably asked why Bharat Biotech's candidate was approved at the same time as AstraZeneca's, when it hasn't even finished or published results from Stage III
Here's a selection of Business Standard opinion pieces for the day
I would go for Bharat Biotech's Covaxin and not Covishield, and that is my personal judgment, the former head of Centre for Advanced Research in Virology at ICMR says
Krishna Ella turns the tables on critics, questions approval granted to Oxford-Astra vaccine
Approval to Covaxin raises many questions
The hasty nod for Bharat Biotech's Covaxin, developed in collaboration with the ICMR and National Institute of Virology, has raised eyebrows in the scientific and healthcare communities
Lauding the people behind this Made in India initiative, Modi said: "The country is proud of the contributions of its scientists and technicians."